July 25th 2024
A single dose of giroctocogene fitelparvovec significantly reduced the mean total annual bleeding rate in patients with moderately severe to severe hemophilia A.
Bristol Myers Squibb Reveals Promising Data for KarXT, a Potential Treatment for Schizophrenia
April 9th 2024A combination of data from the EMERGENT-4 trial and pooled data from the EMERGENT program showed the promise of KarXT (xanomeline-trospium) in providing symptom improvement for people with schizophrenia.
Challenges in Trial Access and Treatment for Women with Chronic Illnesses
March 27th 2024In this Pharmaceutical Executive video interview, Marie Teil, Global Head of UCB’s Women of Childbearing Age Program, discusses the specific challenges women with chronic illnesses face when it comes to accessing and participating in clinical research.
UCB's Women of Childbearing Age Program
March 25th 2024In this Pharmaceutical Executive video interview, Marie Teil, Global Head of UCB’s Women of Childbearing Age Program, talks about the program's creation and their most successful strategies for encouraging the inclusion of women of childbearing age in clinical trials.
Hurdles Hindering the Translation of AI-Powered Research into Tangible Clinical Benefits
March 15th 2024In this Pharmaceutical Executive video interview, Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, discusses why no novel active substances have yet been brought to market through AI technology despite increasing investments in the space for drug discovery as shown in IQVIA's Global Trends in R&D 2024 report.